Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-001-100 in Advanced Solid Tumors With KRAS p.G12C Mutation
jRCT2031220703Phase 2Recruiting
- Sponsor
- D3 Bio
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of elisrasib in Nonhematologic neoplasms (2 arms), sponsored by D3 Bio. Primary endpoints: Number of participants with adverse events and Number of participants with dose-limiting toxicities. Started Oct 2025; status: recruiting.
02
Drugs
elisrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220703.